PFIZER's NORVASC, ZITHROMAX ADD MORE THAN $100 MIL. EACH IN 1st QUARTER; ZOLOFT TOPS U.S. LINE AT $334 MIL.; WORLDWIDE SALES REACH $2.26 BIL. BEFORE LIPITOR AND ARICEPT
Executive Summary
A $94 mil. jump in Zithromax sales during the first quarter in the U.S. made the antibiotic the fastest percentage growing product in Pfizer's domestic line and the single largest new dollar contributor. Pfizer's U.S. pharmaceutical business climbed 17% to just under $1.3 bil. in the first quarter. Zithromax, at $181 mil., showed growth of 108% over $87 mil. in the first quarter last year.